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Using a murine respiratory infection model, we have demonstrated previously that infection with Bordetella
pertussis or immunization with a whole-cell pertussis vaccine induced antigen-specific Th1 cells, which con-
ferred a high level of protection against aerosol challenge. In contrast, immunization with an acellular vaccine,
consisting of the B. pertussis components detoxified pertussis toxin, filamentous hemagglutinin, and pertactin
adsorbed to alum, generated Th2 cells and was associated with delayed bacterial clearance following challenge.
In this study, we demonstrated that addition of interleukin-12 (IL-12) either in vitro or in vivo enhanced type
1 T-cell cytokine responses induced with an acellular vaccine. Furthermore, the rate of bacterial clearance in
mice coinjected with IL-12 and the acellular vaccine was similar to that observed following immunization with
a potent whole-cell vaccine. Analysis of IL-12 secretion by murine macrophages suggested that this cytokine is
produced in vivo following B. pertussis infection or immunization with the whole-cell vaccine. IL-12 was detected
in the supernatants of lung, splenic, and peritoneal macrophages infected with live B. pertussis or stimulated
with heat-killed whole B. pertussis or B. pertussis lipopolysaccharide. In contrast, IL-12 could not be detected
following stimulation of macrophages with the bacterial antigens filamentous hemagglutinin, detoxified per-
tussis toxin, and pertactin, the components of acellular vaccines. Our findings suggest that induction of
endogenous IL-12 may contribute to the high efficacy of pertussis whole-cell vaccines and also demonstrate that
it is possible to attain these high levels of protection with a less reactogenic acellular vaccine incorporating
IL-12 as an adjuvant.
Colonization of the respiratory tract by the gram-negative
coccobacillus Bordetella pertussis results in whooping cough, a
significant cause of morbidity and mortality in human infants.
Immunization with a whole-cell vaccine has proved efficacious
in controlling pertussis, but concern has been raised over its
reactogenicity (6, 30). Pertussis acellular vaccines are signifi-
cantly less reactogenic but of varying efficacy (1, 12, 13, 30).
The rational design of a high-potency acellular vaccine is de-
pendent on a thorough understanding of the mechanism of
immune protection against B. pertussis. Until recently, the bac-
terium was thought to occupy a purely extracellular niche dur-
ing infection, and consequently, humoral immune mechanisms
were assumed to be paramount in protection (30). However,
there is increasing evidence from human and murine studies
that B. pertussis can also occupy an intracellular niche through
invasion and survival within lung macrophages and other cell
types (7, 9, 33). These observations have led to a reexamination
of the mechanisms of protective immunity. While antibody
undoubtedly plays a role in bacterial toxin neutralization and
in the prevention of bacterial attachment following transuda-
tion of circulating immunoglobulin into the lung, evidence is
now emerging that cell-mediated immunity also plays a signif-
icant role in protection against B. pertussis (4, 20, 21, 27–29).
In previous studies (20, 29) using a murine respiratory
model, we have demonstrated that protective immunity against
B. pertussis induced by infection is mediated by a CD41 T-cell
population that secreted interleukin-2 (IL-2) and gamma in-
terferon (IFN-g), namely, Th1 cells (24). Adoptive transfer
experiments demonstrated that protection could be conferred
with T cells in the absence of detectable antibody responses
(20). In a study of vaccine-induced immunity, we have also
reported that immunization with the whole-cell pertussis vac-
cine selectively induced Th1 cells, whereas an acellular vaccine,
consisting of the B. pertussis antigens detoxified pertussis toxin
(PT), filamentous hemagglutinin (FHA), and pertactin, in-
duced Th2 cells (29). Furthermore, the induction of a Th1
response following infection or immunization with the whole-
cell vaccine was associated with earlier bacterial clearance fol-
lowing respiratory challenge.
The polarization of CD41 T-cell cytokine production to-
wards type 1 or type 2 responses following in vivo priming
appears to be controlled by a number of factors, including the
nature of the immunogen, the route of immunization, and the
antigen-presenting cell and the regulatory cytokine milieu at
the site of T-cell stimulation (4, 10, 25). The regulatory cyto-
kine, IL-12, is also a key cytokine in the development of type 1
responses (15, 39). IL-12 can induce the secretion of IFN-g by
NK cells and by CD41 T cells and can promote the differen-
tiation and development of Th1 cells from Th0 precursor pop-
ulations (5, 18, 26, 35). Furthermore, IL-12 may also induce the
production of opsonizing antibodies by promoting IFN-g-me-
diated immunoglobulin (Ig) class switching in favor of IgG2a in
the mouse (23). Since Th1 cells play an important role in the
resolution of infections with intracellular organisms, IL-12 can
influence the course of bacterial, viral, and parasitic infections
by altering the balance of Th1 and Th2 cells in favor of IFN-g
production (8, 11, 14, 16, 26, 34, 38, 40–43).
The aim of the present study was to examine the ability of
live and killed B. pertussis and B. pertussis components to stim-
ulate IL-12 production by macrophages and to investigate
the role of IL-12 in modulating the type of T-cell response to
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B. pertussis induced by immunization. Our findings suggest that
IL-12 is secreted by macrophages following intracellular in-
fection with B. pertussis or stimulation with killed B. pertussis
(whole-cell vaccine) but not with acellular vaccine components.
Furthermore, we have demonstrated that a Th2 response nor-
mally induced following immunization of mice with an acellu-
lar vaccine preparation can be switched to a Th1 or Th0 re-
sponse by incorporation of IL-12 into the vaccine formulation.
The use of IL-12 as an adjuvant in an acellular pertussis vac-
cine significantly increased its protective efficacy; the rate of
B. pertussis clearance from the lungs following respiratory chal-
lenge was equal to that observed with a potent whole-cell
vaccine. Our findings demonstrate a regulatory influence of IL-
12 on the induction of B. pertussis-specific Th1 cells following
infection or immunization and provide further evidence for the
role of Th1 cells in protective immunity against B. pertussis.
MATERIALS AND METHODS
Mice. Female BALB/c mice were bred and maintained under the guidelines of
the Irish Department of Health. All mice were 8 to 12 weeks old at the initiation
of experiments.
Cytokines and antigens. Recombinant murine IL-12 was kindly provided by
Stanley Wolf, Genetics Institute Inc., Cambridge, Mass. The third British refer-
ence preparation for pertussis vaccine (88/522) was used as the whole-cell vac-
cine. Heat-killed B. pertussis for use in proliferation assays was prepared by
incubation of cells at 808C for 30 min. PT, FHA, and pertactin, prepared from
B. pertussis Tohama, were kindly provided by Carine Capiau at SmithKline
Beecham, Rixensart, Belgium. Chemically detoxified PT (PTd) for immunization
experiments was prepared by treatment with 0.2 to 0.5% formaldehyde for 7 days
followed by dialysis against phosphate-buffered saline (PBS) containing 0.01%
formaldehyde. Inactivated PT (iPT) for use in proliferation assays was prepared
by heating active PT at 808C for 30 min (active PT refers to untreated native PT
throughout). Lipopolysaccharide (LPS) from B. pertussis W28 (89/670) was ob-
tained from The National Institute for Biological Standards and Control, Potters
Bar, Hertfordshire, United Kingdom. LPS from Escherichia coli (prepared by
phenolic extraction and gel filtration chromatography) was purchased from
Sigma Chemical Co., Poole, Dorset, United Kingdom.
Immunizations. In studies of the adjuvant effect of IL-12 for a pertussis
acellular vaccine, groups of 20 mice received two intraperitoneal immunizations
4 weeks apart with one-fifth of a human dose (0.8 IU) of the whole-cell vaccine
(88/522) or an acellular vaccine consisting of 5 mg each of FHA, pertactin, and
PTd with or without recombinant murine IL-12 (0.5 mg per mouse). Control mice
received PBS alone. Two weeks after the second immunization, the mice were
either sacrificed to assess immune responses or challenged with B. pertussis.
Aerosol infection. Respiratory infection of mice was initiated by aerosol chal-
lenge by the method originally described by Sato et al. (32), with the following
modifications. B. pertussis W28 phase I was grown under agitation conditions at
368C in Stainer-Scholte liquid medium. Bacteria from a 48-h culture were resus-
pended at a concentration of approximately 2 3 1010 CFU/ml in physiological
saline containing 1% casein. The challenge inoculum was administered as an
aerosol over a period of 12 min with a nebulizer directed into an aerosol chamber
containing groups of 20 to 24 mice. Four mice from each experimental group
were sacrificed at 2 h and 2, 5, and 9 days after aerosol challenge to assess the
number of viable B. pertussis bacteria in the lungs.
Enumeration of viable bacteria in the lungs. Lungs were removed aseptically
and homogenized in 1 ml of sterile physiological saline with 1% casein on ice.
One hundred microliters of undiluted homogenate or of serially diluted homog-
enate from individual lungs were spotted in triplicate onto each of three Bordet-
Gengou agar plates, and the number of CFU was estimated after 5 days of
incubation. Results are reported as the mean number of B. pertussis CFU for
individual lungs from four mice. The limit of detection was approximately 0.5
log10 CFU per lung.
Macrophage production of IL-12. Murine peritoneal macrophages were ob-
tained from naive animals by plastic adherence of cells obtained by peritoneal
lavage. Splenic macrophages were prepared by plastic adherence, and alveolar
macrophages were isolated by bronchoalveolar lavage as described previously
(29). The murine macrophage cell line J774 was also used in studies of IL-12
production. Macrophages were infected with viable phase I B. pertussis bacteria
at a bacterium-to-macrophage ratio of 5:1 for 2 h before extensive washing.
Extracellular bacteria were killed by treatment with polymyxin B sulfate (100
mg/ml) for 40 min followed by further washing. This treatment reduces the
number of extracellular bacteria by 5.0 log10 CFU. Infected macrophages or
macrophages stimulated with heat-inactivated bacteria or bacterial antigens were
cultured at 2 3 105 cells per ml at 378C in a 5% CO2 atmosphere. After 24 or
48 h, cell culture supernatants were removed and the production of IL-12 was
determined by bioassay or immunoassay.
T-cell proliferation assays. Spleen cells from immunized or control mice were
tested for in vitro proliferation against heat-killed B. pertussis (106/ml), heat-
inactivated PT (1.0 mg/ml), FHA (1.0 mg/ml), and pertactin (1.0 mg/ml) as
described previously (20). Results were calculated as mean counts per minute of
[3H]thymidine incorporation for triplicate cultures for groups of four to six mice.
Stimulation indices were calculated by dividing the proliferative response to the
antigens by the response of control cultures, in which cells were stimulated with
medium alone.
Analysis of cytokine production. T-cell cytokine production was assessed with
spleen cells stimulated with B. pertussis antigens in vitro. Spleen cells (2 3
106/ml) from immunized or naive control mice were cultured with antigens or
with medium alone (background control), and supernatants were removed after
24 h to determine IL-2 and after 72 h to determine IFN-g, IL-4, and IL-5. IL-2
release was assessed by the ability of culture supernatants to support the prolif-
eration of the IL-2-dependent CTLL-2 cell line, and the concentrations of mu-
rine IL-4, IL-5, and IFN-g were determined by specific immunoassays using
commercially available antibodies (PharMingen, San Diego, Calif.) as described
previously (17). IL-12 was determined by immunoassay and bioassays. In the
immunoassay, commercially available (Genzyme Diagnostics, Cambridge, Mass.)
anti-IL-12 monoclonal antibodies, clones C17.8 (rat IgG2a) and C15.6 (rat
IgG1), which recognize the p40 subunit of murine IL-12 either as a monomer, as
homodimers, or as part of the p70 heterodimer, were used for capture and
detection, respectively. An alkaline phosphatase-conjugated mouse anti-rat IgG1
(PharMingen) was used to detect the second anti-IL-12 antibody. Biologically
active IL-12 concentrations were assessed by the ability of test supernatants to
stimulate the production of IFN-g by naive spleen cell preparations. To ensure
that the production of IFN-g was due to the presence of IL-12, test samples were
also assayed in the presence and absence of a specific anti-IL-12 neutralizing
antibody (2.5 mg of protein G-purified sheep anti-murine IL-12 per ml; provided
by Stanley Wolf, Genetics Institute, Inc., which can completely neutralize up to
5 ng of IL-12 per ml. Cytokine concentrations were determined by comparing
either the proliferation or the optical density at 492 nm for test samples with a
standard curve for recombinant cytokines of known concentration.
RESULTS
Macrophages secrete IL-12 in response to live or killed
B. pertussis. Our previous studies have demonstrated that re-
spiratory infection with B. pertussis or immunization with the
pertussis whole-cell vaccine selectively stimulates Th1 cells in
vivo, whereas an acellular vaccine consisting of PTd, FHA, and
pertactin adsorbed to alum generated predominantly Th2 cells
(4, 29). One explanation for this dichotomy may be the induc-
tion of endogenous IL-12 secretion by macrophages exposed to
live or killed whole bacteria or bacterial components not
present in the acellular vaccine. Therefore, we examined the
ability of killed whole B. pertussis and B. pertussis components
to stimulate the production of IL-12 by murine macrophages.
Adherent cells from the spleens of naive mice stimulated with
heat-killed B. pertussis produced significant levels of IL-12, as
detected by an immunoassay specific for p40 and p70 (Fig. 1A).
Moderate levels of IL-12 were also detected in supernatants
from macrophages incubated with LPS derived from either
B. pertussis or another gram-negative bacterium, E. coli. These
levels were enhanced when IFN-g was added to the cultures
(data not shown). In contrast, little or no IL-12 was produced
by macrophages stimulated with FHA, PTd, or pertactin, the
components of the acellular vaccine (Fig. 1A). Peritoneal mac-
rophages also produced IL-12 in response to stimulation with
heat-killed B. pertussis in a dose-dependent manner (Fig. 1A).
To demonstrate that the IL-12 produced was biologically
active, we also tested IL-12 production with a bioassay which
measured the production of IFN-g by murine spleen cells in
the presence or absence of a neutralizing polyclonal anti-IL-12
antibody. Supernatants from splenic macrophages that had
been stimulated with killed bacteria or purified LPS induced
naive spleen cells to produce high levels of IFN-g, which was
inhibited by the anti-IL-12 antibody (Fig. 1B). Although su-
pernatants from spleen cells stimulated with active PT did
stimulate the production of IFN-g, this response could not be
ablated by the addition of the anti-IL-12 antibody. Further-
more, IL-12 was not detected in supernatants of PT-stimulated
macrophages by the immunoassay (Fig. 1A). Therefore, it is
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unlikely that active PT induces IL-12 from macrophages. Ac-
tive PT is mitogenic for murine T cells, and we have found that
it promotes IFN-g produced by purified splenic T cells in the
presence of irradiated accessory cells (31a). Therefore, the
IFN-g detected in the IL-12 bioassay with supernatants from
macrophages stimulated with active PT is likely to result from
direct stimulation of T cells in the spleen cell population by
active PT carried over in the macrophage supernatants.
Consistent with previous reports (9, 33), we found that live
B. pertussis can be taken up and survive within macrophages.
We therefore examined the production of IL-12 by macro-
phages following infection with B. pertussis. Murine macro-
phages from different sources were cultured with live B. per-
tussis for 2 h, washed extensively, and treated with antibiotics
to remove extracellular organisms. Culture supernatants were
tested for IL-12 after 24 and 48 h. The results in Table 1
demonstrate that murine macrophages derived from the lungs
or peritoneal cavity or in the form of an established cell line
produce biologically active IL-12 when infected with B. pertus-
sis. Although the levels of IL-12 are not as high as that ob-
served following stimulation of peritoneal macrophages with
killed bacteria (Fig. 1A), this may reflect the lower concentra-
tion of live bacteria used in this experiment. Higher levels of
viable B. pertussis bacteria were employed in other experiments
but resulted in cell death of the macrophage populations used
in vitro. In separate experiments, supernatants of alveolar,
peritoneal, J774, and splenic macrophages removed 24 and
48 h after infection with B. pertussis were also found to contain
IL-12 detected by the immunoassay (data not shown). Further-
more, peritoneal macrophages recovered from mice 24 h after
intraperitoneal injection with live B. pertussis secreted signifi-
FIG. 1. Macrophage production of IL-12 in response to whole B. pertussis cells and bacterial components. IL-12 was tested by immunoassay (A) or by bioassay (B).
Results from the immunoassay, which detects p40 and p70, are mean concentrations in supernatants from triplicate cultures of splenic macrophages incubated with
heat-killed B. pertussis (1 3 108/ml and 5.0 3 108/ml), B. pertussis LPS (1 mg/ml), E. coli LPS (1 mg/ml), FHA (1 mg/ml), pertactin (1 mg/ml), active PT (1 mg/ml), PTd
(1 mg/ml), or peritoneal macrophages incubated with increasing doses (105 to 108 CFU/ml) of heat-killed B. pertussis. The bioassay measured the production of IFN-g
by naive spleen cells incubated for 24 h with supernatants from splenic macrophages (stimulated as described for the immunoassay) in the presence or absence of a
polyclonal neutralizing anti-IL-12 at 2.5 mg/ml. Levels of IFN-g produced in the presence of anti-IL-12 antibody are only shown where positive responses were observed
in the absence of the antibody and with one dose (5.03 108/ml) of the killed bacteria. Results are means for triplicate assays and are representative of four independent
experiments. Standard deviations were less than 20% of the mean values.
TABLE 1. Murine macrophages secrete IL-12 following
infection with B. pertussisa
Macrophage type Infected
IFN-g (pg/ml)b
2Ab 1Ab
Alveolar 2 ,50 ,50
1 700 (641) 100 (616)
Peritoneal 2 ,50 ,50
1 30,000 (62,245) 75 (631)
J774 2 ,50 ,50
1 900 (666) ,50
aMacrophages were infected with B. pertussis for 2 h and extensively washed
and treated with polymyxin B to kill extracellular bacteria prior to culture in the
presence (1Ab) or absence (2Ab) of a neutralizing anti-IL-12 antibody. IL-12
production was assessed with a bioassay which measured the production of
IFN-g by naive spleen cells incubated for 24 h with supernatants from infected
(1) or control uninfected (2) macrophages.
b Results are expressed as the mean (6 standard deviation) IFN-g concentra-
tions in the supernatants of triplicate cultures measured by immunoassay.
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cant levels of IL-12 (569 pg/ml of culture supernatant in one
experiment) without further stimulation in vitro.
Antigen activation of T cells in vitro in the presence of IL-12
modulates an established Th2 response. Immunization of mice
with FHA and PTd adsorbed to alum generated a potent Th2
response; ex vivo spleen cells produced high levels of IL-5 and
low levels of IFN-g following specific antigen stimulation in
vitro (Fig. 2). However, the addition of 0.2 or 2.0 ng of recom-
binant murine IL-12 per ml to the spleen cells during antigen
stimulation in culture resulted in significantly increased con-
centrations of IFN-g and marginally reduced levels of IL-5
(Fig. 2), demonstrating that IL-12 can modulate the pattern of
in vitro cytokine secretion by in vivo-primed T cells.
Enhanced T-cell proliferative responses and type 1 cytokine
secretion following coinjection of B. pertussis antigens with
IL-12 in the presence or absence of alum.We tested the ability
of IL-12 to modulate immune responses to B. pertussis antigens
in vivo by immunization of mice with FHA and PTd in the
presence or absence of alum. Two weeks after immunization
with FHA and PTd in solution, the in vitro proliferative re-
sponses of spleen cells against the specific antigens were sim-
ilar to that observed against medium alone (Table 2). In con-
trast, immunization with FHA and PTd in the presence of IL-
12 resulted in enhanced proliferative responses to FHA, iPT
(Table 2), and killed whole bacteria (data not shown). The
addition of IL-12 to the alum-adsorbed antigens also augment-
ed the B. pertussis-specific proliferative responses, although
this did not reach a level of statistical significance (Table 2).
Coinjection of soluble antigens and IL-12 enhanced the level
of IFN-g secreted in vitro by antigen-stimulated spleen cells;
IL-5, a Th2 type cytokine, was not detected from spleen cells
from these animals (Table 2). In contrast, spleen cells from
mice immunized with FHA and PTd in the presence of alum
secreted high levels of IL-5 and moderate levels of IFN-g,
confirming the known effect of alum to favor the induction of
Th2 type responses in mice. However, coinjection of IL-12 with
FHA and PTd adsorbed to alum resulted in a reduction in IL-5
production but not a significant increase in the level of IFN-g
secreted, when compared with spleen cells from animals which
had received antigens formulated with alum in the absence of
IL-12 (Table 2).
Incorporation of IL-12 in a pertussis acellular vaccine aug-
ments protection against B. pertussis challenge by promoting
the induction of Th1 cells. Since we had previously demon-
strated that a highly protective whole-cell vaccine induces a
Th1 response, we decided to compare the immune responses
and levels of protection induced with a whole-cell vaccine and
with an acellular vaccine administered in the presence or ab-
sence of IL-12. Groups of mice received two immunizations 4
weeks apart with either a whole-cell vaccine, an acellular vac-
FIG. 2. Addition of IL-12 in vitro augments IFN-g production by spleen cells
from mice primed for a Th2 response. Mice were immunized with FHA and PTd
in alum, and spleen cells were stimulated in vitro with FHA or iPT (1.0 mg/ml)
or medium alone in the presence of 0, 0.2, and 2.0 ng of recombinant murine
IL-12 per ml. The levels of IFN-g and IL-5 were tested in spleen cell superna-
tants after 72 h. Results are expressed as the mean (6 standard error) cytokine
concentration for stimulated spleen cells from four mice per group tested in
triplicate.
TABLE 2. Coinjection with IL-12 augments cellular immune responses to B. pertussis antigensa
Immunization In vitrostimulation
Proliferation
IFN-g (ng/ml) IL-5 (pg/ml)
cpm SI
FHA 1 PTd Medium 118 6 40 2 2
FHA 129 6 53 1.1 6 0.4 1.8 6 0.5 2
iPT 98 6 34 0.8 6 0.4 2.2 6 0.8 2
FHA 1 PTd 1 IL-12 Medium 1,347 6 191 2 2
FHA 8,412 6 1,491 6.2 6 0.9* 12.3 6 1.0** 2
iPT 8,985 6 3,793 6.7 6 1.6* 11.0 6 0.9** 2
FHA 1 PTd 1 alum Medium 2,380 6 168 2 2
FHA 13,264 6 3,010 5.6 6 2.8 5.7 6 0.6 410 6 70
iPT 6,389 6 2,123 2.7 6 0.8 12.1 6 1.3 430 6 60
FHA 1 PTd 1 alum 1 IL-12 Medium 1,546 6 823 2 2
FHA 17,953 6 4,436 11.6 6 3.4 7.4 6 3.0 140 6 30*
iPT 7,706 6 4,128 5.0 6 3.0 16.3 6 2.0 110 6 20*
a Spleen cells from mice immunized with soluble or alum-adsorbed FHA and PTd, with or without IL-12 (0.5 mg), were stimulated in vitro with iPT (1.0 mg/ml), FHA
(5.0 mg/ml), or medium alone. Proliferative responses were measured by [3H]thymidine incorporation after 4 days and are expressed as counts per minute and
stimulation indices (SI). The levels of IFN-g and IL-5 were tested in supernatants after 72 h of culture. Results are mean (6 standard deviation) responses for triplicate
cultures for four mice in each group. 2, below the level of detection. * and **, P , 0.01 and P , 0.001, respectively, compared with the corresponding value for mice
immunized in the absence of IL-12, determined by Student’s t test.
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cine preparation in solution in the presence or absence of
IL-12 (0.5 mg per mouse), or PBS alone as a control. Mice were
challenged by exposure to a B. pertussis aerosol 2 weeks after
the second immunization, and the course of infection was
monitored by performing CFU counts on the lungs at intervals
after respiratory challenge. The levels of bacteria in the control
mice were still high 9 days after challenge (Fig. 3). The time
course of respiratory infection in mice immunized with the
whole-cell vaccine was very short, with complete clearance by
day 5. Bacterial clearance in mice immunized with the acellular
vaccine was slower; complete clearance did not occur until day
9 postchallenge. However, the addition of IL-12 to the acellu-
lar vaccine formulation significantly enhanced its protective
efficacy. Bacterial clearance was complete by day 5, and the
bacterial burden on day 2 was lower than that observed in mice
immunized with the whole-cell vaccine (Fig. 3).
To confirm our earlier suggestions on the protective role of
Th1 cells, and to establish that the superior protective efficacy
observed with the acellular vaccine injected with IL-12 was due
to enhanced cell-mediated immunity, we tested the immune
response of the immunized mice on the day of challenge.
Proliferative responses were detected against whole killed
B. pertussis, FHA, iPT, and pertactin in spleen cells from mice
immunized with the acellular vaccine, but these were signifi-
cantly enhanced in the presence of IL-12 and approached the
levels observed with the whole-cell vaccine (reference 29 and
data not shown). An examination of the cytokine profiles pro-
duced by spleen cells stimulated with specific antigen in vitro
revealed that spleen cells derived from mice immunized with
the whole-cell vaccine secreted IL-2 and IFN-g but no detect-
able IL-5 (Fig. 4). In contrast, spleen cells from mice which
received the acellular vaccine in the absence of IL-12 secreted
low levels of IL-2 and IFN-g and low but detectable levels of
IL-5. However, spleen cells from mice immunized with the
acellular vaccine in the presence of IL-12 secreted significant
levels of IL-2 and IFN-g. Interestingly, IL-12 appeared to have
differential effects on T cells of different antigen specificities,
potentiating IL-2 production by T cells specific for FHA and
pertactin and IFN-g production by PT-specific T cells. Overall,
the immune response induced with the acellular vaccine incor-
porating IL-12 as an adjuvant is best described as a mixed
Th1-Th2 or Th0 profile.
DISCUSSION
The significant new findings of this study are that tissue
macrophages, including those recovered from the lungs,
spleen, or peritoneal cavity of naive mice, produce IL-12 fol-
lowing exposure to live or killed B. pertussis and that the ad-
dition of IL-12 as an adjuvant to a pertussis acellular vaccine
enhances its protective efficacy by promoting type 1 T-cell
cytokine production. We have demonstrated that immuniza-
FIG. 4. IL-12 switches a Th2 to a Th1-Th0 response with an acellular per-
tussis vaccine. Mice were immunized as described in the legend to Fig. 3, and the
secretion of IL-2, IFN-g, and IL-5 was tested following stimulation of spleen cells
with iPT (0.2 to 1.0 mg/ml), FHA (0.2 to 5.0 mg/ml), and pertactin (0.2 to 5.0
mg/ml). Results are expressed as the mean cytokine concentration to the opti-
mum concentration of antigen for spleen cells from four mice per group tested
in triplicate.
FIG. 3. IL-12 as an adjuvant enhances the protective efficacy of an acellular
pertussis vaccine. BALB/c mice were immunized at 0 and 4 weeks with a whole-
cell vaccine (WCV), an acellular vaccine (5 mg each of soluble PTd, FHA, and
pertactin) with or without 0.5 mg of IL-12 (ACV1 IL-12 and ACV, respectively),
or PBS alone (control). Mice were challenged by aerosol inoculation with B. per-
tussis 2 weeks after the second immunization. The course of respiratory infection
was monitored by performing viable counts at intervals after challenge. Results
are mean (6 standard error) CFU counts performed on individual lungs in
triplicate for four mice per group at each time point.
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tion of mice with a pertussis acellular vaccine consisting of
PTd, FHA, and pertactin adsorbed to alum generated a Th2
response in mice and was associated with delayed bacterial
clearance following respiratory challenge (4, 29). In contrast,
previous infection or immunization with a whole-cell vaccine
induced Th1 cells and conferred a high level of protection
(20, 28, 29). Here we provide one explanation for the Th1-Th2
cell dichotomy in acquired immunity to B. pertussis. We dem-
onstrate that macrophages secrete IL-12 following infection
with B. pertussis or stimulation with the whole-cell vaccine or
B. pertussis LPS but not with PT, FHA, or pertactin, the com-
ponents of the acellular vaccine. Furthermore, the addition of
exogenous IL-12 to the acellular vaccine results in a switch in
the response from Th2 to Th1 or Th0 and significantly aug-
mented bacterial clearance following respiratory challenge,
such that the protective efficacy exceeded that observed with a
potent whole-cell vaccine.
Since colonization of the respiratory tract by B. pertussis was
considered to be exclusively extracellular, it has long been
assumed that vaccine-induced immunity is mediated through
the generation of humoral immune responses (6, 30). There-
fore, it might be predicted that protection would be associated
with a type 2 T-cell response. While it is likely that local or
serum antibodies that have transudated into the lung do play a
role in preventing bacterial attachment and in the neutraliza-
tion of bacterial toxins, there is now convincing evidence that
cell-mediated immunity is also required for clearance of bac-
teria from the lungs (4, 20, 21, 27–29). We have previously
demonstrated the involvement of Th1 cells (4, 29), and the
present study provides evidence of a role for IL-12 in protec-
tive immunity against B. pertussis. It has been reported that
endogenously produced IL-12 plays a role in resistance to a
number of intracellular pathogens, such as Leishmania major,
Schistosoma mansoni, Toxoplasma gondii, Listeria monocyto-
genes, Cryptosporidium parvum, Brucella abortus, andMycobac-
terium tuberculosis, through the generation of a robust Th1
response (8, 11, 14, 16, 38, 40–43). The present study demon-
strates that murine macrophages, including those obtained
from the lungs, peritoneal cavity, and spleen, produce IL-12 in
response to infection with B. pertussis or stimulation with heat-
killed bacteria. This provides indirect evidence of a role for
endogenous IL-12 in immunity to B. pertussis following respi-
ratory infection or immunization with the whole-cell pertussis
vaccine.
The whole-cell pertussis vaccine, which is composed of heat-
killed bacteria, is effective at preventing whooping cough in
vaccinated infants, and it has been suggested that the efficacy
of this vaccine may be related to levels of LPS as well as
residual active PT (3, 6, 30). The results of the present study
demonstrate that LPS appears to be a major component of
B. pertussis responsible for stimulating IL-12 production by
macrophages. However, since IFN-g augments IL-12 produc-
tion by macrophage in response to LPS (37), PT may also be
involved in initiating the cytokine cascade through the stimu-
lation of IFN-g secretion by T cells (31a). This suggests that
the high protective efficacy of whole-cell vaccines may reside in
part in their ability to induce IL-12 through the presence of low
but significant levels of LPS and active PT. Paradoxically, cer-
tain of the unwanted side effects of the whole-cell vaccine have
also been attributed to LPS and active PT (6, 36). Indeed,
concerns over the reactogenicity of the whole-cell vaccine have
led to considerable interest in the development of efficacious
subunit or acellular vaccines against B. pertussis. Recent clini-
cal trials have demonstrated that certain acellular vaccines are
effective at preventing severe disease in infants when adminis-
tered with alum as the adjuvant (12, 13). Although alum is the
adjuvant of choice for human use, we and others have shown
that immunization with purified native or recombinant pro-
teins adsorbed to alum favors the induction of Th2 responses
in mice (4, 22). Furthermore, analysis of cytokine production
by peripheral T cells from infants immunized with a pertussis
acellular vaccine revealed a mixed Th1-Th2 or Th0 profile
(31). Our studies with the murine respiratory model clearly
indicated that early bacterial clearance following respiratory
challenge of immune mice is associated with the induction of T
cells that secrete IL-2 and IFN-g (4, 29).
IL-12 has been shown to possess adjuvant properties in a
murine model of vaccine-mediated protection against Leish-
mania major, Listeria monocytogenes, T. gondii, and a neuro-
tropic herpesvirus through the preferential induction of Th1
type responses (2, 11, 19, 34). In the present study, we dem-
onstrate that coinjection of IL-12 with a pertussis acellular
vaccine enhances cell-mediated responses to B. pertussis anti-
gens and significantly improves its protective efficacy against
respiratory challenge. Incorporation of IL-12 into the vaccine
formulation enhanced the levels of type 1 cytokines, in particu-
lar, IFN-g. The pattern of antigen-specific T-cell cytokine se-
cretion was also altered when administered with alum-ad-
sorbed antigens, an adjuvant which strongly favors a polarized
Th2 response in mice. The addition of IL-12 in this situation
results in a reduction in the levels of IL-5 observed and an
increase in IFN-g, demonstrating the ability of IL-12 to mod-
ulate T-cell responses even under conditions favorable to the
induction of a Th2 response. Furthermore, the addition of IL-
12 to cultures of spleen cells from mice immunized with an
acellular vaccine promoted antigen-induced IFN-g production.
This suggests that IL-12 is also capable of switching on type 1
cytokine production by T-cell populations which appeared to
be primed for a type 2 response.
It is not known which of the pleiotropic effects of IL-12
enhance vaccine-mediated bacterial clearance. We have previ-
ously suggested that B. pertussis-specific cell-mediated immu-
nity may be required for the destruction of an intracellular
reservoir of bacteria in the lungs (20, 21). The present findings
are consistent with this model in which the presence of IL-12
in an acellular vaccine formulation enhances IFN-g production
by B. pertussis-specific Th1 cells, which augments bacterial
clearance by activating the intracellular killing of bacteria by
macrophages. Furthermore, the induction of a Th1 response
promoted by IL-12 may enhance bacterial uptake by macro-
phages through the induction of B. pertussis-specific opsonizing
antibody.
In conclusion, the present study demonstrates that murine
macrophages secrete IL-12 when stimulated with live or killed
B. pertussis but not with the putative protective antigens FHA,
PT, or pertactin. One mechanism whereby the whole-cell vac-
cine generates an efficacious Th1 response might be through
macrophage production of IL-12 in vivo in response to LPS or
other components of the killed bacterial preparation. Con-
versely, the poor production of IL-12 from macrophages stim-
ulated with components of the acellular vaccine may explain
the predominant Th2 response in mice immunized with this
vaccine. The adjuvant properties of IL-12 and its ability to
modulate the profile of cytokines secreted by CD41 T-cell
populations suggest that IL-12 might prove a useful addition to
more efficacious acellular vaccines against pertussis.
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